Table 2.
Mode | Imaging modalities | Advanced composites | Particle size (nm) | Pore size (nm) | Contrast agent | Animal model | Refs |
---|---|---|---|---|---|---|---|
Single-mode | T1-MRI | MnOx-HMSNs | 200 | 4.4 | MnOx | Rats | [459] |
MRI | fmSiO4@SPIONs | 50 | 2.8 | SPIONs | Mice | [345] | |
T1 MRI | mSiO2@GGO NPLNPs | 50 | – | Cr3+, Nd3+, Gd3Ga5O12 | Kunming mice, BALB/c mice | [347] | |
T1/T2 MRI | MnFe2O4@ mSiO2 | 50 | 2.4 | MnFe2O4 | Kunming mice | [344] | |
T1/T2 MRI | Fe3O4@MnO/mSiO2 | 45 | 2.5 | Fe3O4@MnO | – | [460] | |
Dual-mode | T1/T2 MRI, FL | Fe3O4@mSiO2 | 45–105 | 2–3 | FITC, RITC | Balb/c mice | [15] |
T2 MRI, FL | Fe3O4-MSN | 70 ± 6 | 2.3 | FITC, RITC | Balb/c mice | [461] | |
PET, CT | 89Zr-labelled MSNs | 180 | 8 | 89Zr | SCID mice | [366] | |
FL, T1 MRI | MSN@QDs | 101.2 | 3.9 |
Mn-doped ZnSe QDs |
Balb/c mice | [182] | |
UCL, CT | UCNPs@mSiO2-POM @FC | 120 | – | Yb | Kunming mice | [462] | |
FL, PAI |
17AAG@HMONs- Gem-PEG |
60 | – | ICG | Balb/c mice | [463] | |
TPF, T2 MRI |
Fe3O4@CDs@mSiO2 @PTX@mSiO2 |
91 | 2.9 | Fe3O4, CDs | Balb/c mice | [464] | |
T2 MRI, PL | CoFe2O4@mSiO2 | 52 | 8 | - | – | [465] | |
T1 MRI, FL | MS‐Gd2O3:Eu@PEG | 190 in length, 70 in width | ~ 4 | Gd2O3 | – | [211] | |
T2 MRI, FL |
Fe3O4@mSiO2 -CD-FA |
100–150 | 4.72 | CD, Fe3O4 | – | [466] | |
T1 MRI, PL | GdVO4:Eu3+@mSiO2 | 75 | 3.3 | GdVO4, Eu3+ | – | [361] | |
19F MRI, FL | Au-FMSNs | ~ 100 | < 1.2 | Au, C6F6, FITC | – | [467] | |
T2 MRI, FL | MSN-Gd | > 75 | 1.4–2.9 | Gd3+ | – | [468] | |
UCL, PAI | UCNP@mSiO2-ICG | ~ 60 | – | Nd, Er, ICG | ND4 Swiss Webster mice | [270] | |
T2 MRI, CT |
M-MSN(Dox/Ce6)/ PEM/P-gp shRNA |
280 ± 17 | 2.482 | Fe3O4-Au | Balb/c mice | [264] | |
T1 MRI, UCL |
NaYF4: Yb/Er@NaGdF4@ SiO2@mSiO2 |
240–265 | 2.23, 4.01 | Gd | Balb/c mice | [469] | |
T1 MRI, FL | Gd-Al@MSNs | 57 | 2.5 | Gd-Al, Cy5 | Balb/c mice, Kunming mice | [470] | |
UCL, CT | Y2O3:Yb, Er@mSiO2 | 340 | 4.6 |
Y2O3:Yb, Er |
Balb/c mice | [471] | |
FL, CT | A-AuNC@PAA/mSiO2 | 120 | 2 | Au | Balb/c mice | [472] | |
MRI, UCL | β‐NaYF4:Yb3+, Er3+ @β‐NaGdF4:Yb3+@mSiO2 | 78 | 2.9 |
β‐NaYF4: Yb3+, Er3+ @β‐NaGdF4: Yb3+ |
Kunming mice | [473] | |
T1 MRI, UCL | MUCNCs@SNTs | 95 in wall thickness | 5 |
NaYF4:Yb/ Er/Gd |
– | [474] | |
T2 MRI, FL |
Hydrazine-MSN- FITC-Fe3O4-PEG |
– | – | Fe3O4, FITC | – | [353] | |
Multi-mode | FL, MRI, CT | WS2-IO@MS-PEG | – | 2.48 | WS2, Iron oxide | Balb/c mice | [141] |
PAI, PET, FL | CuSNDs@DOX-MSNs | 100 | 6 | CuSNDs | Nude mice | [475] | |
US, CT, PAI, Thermal | HMSs@Au-PFH-mPEG NSs | 200 | 3.8 | Au | Balb/c mice | [374] | |
T2 MRI, FL Thermal | Au-NRs-MMSNEs | 300 × 180 | 2–3.5 | Au, Fe3O4 | SD mice | [142] | |
PT, FL, T1 MRI | RGD-CCmMC | 116.5 | 2.9 ± 0.3 | Mn-Cdots, gold cube-in-cube | Balb/c mice | [476] | |
T2 MRI, US, FL | mSiO2-MNPs | 9.4 ± 1.2 | 2, 4 | Fe3O4, FITC | – | [370] | |
TPL, TPEF, FL, PAI, PT | GNR@mSiO2-5-FU | 54.14 ± 4.39 in length and 15.87 ± 1.28 in width, a shell of 19.85 ± 1.67 | GNRs, ICG | Balb/c mice | [477] | ||
SR‐STXM, CT, T1 MRI, PA | Au@SiO2(Gd)@HA | 232.7 | – | Gd | Balb/c mice | [346] | |
T2 MRI, PAI, BL | GRMNBs | 130 | 2.1 | Au, Fe3O4 | C57BL/6 mice | [371] | |
PAI, MRI, FL | Au@SiO2 | 200 | 4.6 | AuQDs | CD1 mice | [478] | |
UCL, CT, PT, T1/T2 MRI |
GdOF: Ln@SiO2– ZnPc-CDs-FA |
293 | 3.53 | GdOF, ZnPc, CDs | Balb/c mice | [479] | |
T1 MR, CT, UCL | UCMSNs | - | 3.1 | Yb3+, Gd3+ | Balb/c mice | [273] | |
T1 MRI, PET, FL | MSN@Gd@64Cu | ~ 60 | - | Gd3+, 64Cu, FITC | Balb/c mice | [358] | |
T1 MRI, FL, US | MSN-Gd | 384 ± 134 nm | 4.1 ± 1.1 nm | GdCl3, Fluorescein | nude mice | [480] | |
US, CEUS, T2 MRI |
Fe-HSNs | 200.3 ± 15.2 | 6.03 | - | C57BL mice, ApoE-/- mice | [368] | |
T2 MRI, CT, FL | i-fmSiO4@SPIONs | 50 | 2.7 | Fe3O4 | – | [373] |
17-AAG: 17-N-allylamino-17-demethoxygeldanamycin or Tanespimycin; 5-FU: 5-Fluorouracil; A-AuNC: Aggregated gold nanocluster; Al: Aluminum; Au: Gold; BL: Bioluminescent; CDs: Carbon dots; CEUS: Contrast-enhanced ultrasound; Ce6: Chlorin e6; CPT: Camptothecin; CT: Computed tomography; Cu: Copper; Cy 5: Cyanine 5; DOX: Doxorubicin; FA: Folic acid; FITC: Fluorescein isothiocynate; FC: Folate-chitosan; FL: Fluorescence; FMSNs: Fluorescein-functionalized MSNs; Gd: Gadolinium; Gem: Gemcitabine; GNR@mSiO2: Mesoporous silica‐coated gold nanorods; GRMNBs: Multi‐gold nanorods crystal‐seeded magnetic mesoporous silica nanobeads; HA: Hyaluronic acid; HMONs: Hollow mesoporous organosilica nanocapsule; HMS -Hollow mesoporous silica; HSN: Hollow silica nanoparticles; i-fmSiO4@SPIONs: Iodinated oil-loaded mesoporous silica-coated superparamagnetic iron oxide nanoparticles; ICG: Indocyanine green; mC: Magnetic carbon; MMSNEs- Magnetic mesoporous silica nanoellipsoids; Mn: Manganese; MNPs: Mesoporous silica-coated magnetic nanoparticles; mPEG: Methoxypoly(ethylene glycol); MRI: Magnetic resonance imaging; mSiO2 or MS: Mesoporous silica; MSNs: mesoporous silica nanoparticles; MUCNCs@SNTs: Silica nanotubes functionalized with NaYF4:Yb/Er/Gd nanocrystals; NPLNPs: Near-infrared persistent luminescence nanoparticles; NRs: Nanorods; NSs: Nanostars; P-gp: P-glycoprotein; PAA: Polyacrylic acid; PAI: Photo acoustic imaging; PEG: Poly(ethylene glycol); PEM: Alginate/chitosan-based polyelectrolyte multilayers; PET: Positron emission tomography; PFH: Perfluorohexane; PL: Photoluminescence; POM: Polyoxometalate; PT: Photothermal; PTX: Paclitaxel; QDs: Quantum dots; RITC: Rhodamine isothiocyanate; ShRNA: small hairpin ribose nucleic acid; SR-STXM: Synchrotron radiation scanning transmission X‐ray microscopy; TA: Trimethylammonium groups; TPEF: Two‐photon excitation fluorescence; TPF: Two‐photon fluorescence; TPL: Two‐photon luminescence; TRF: Transferrin; UCNPs: Upconversion nanoparticles; UCL: Upconverting luminescence; UMSCs: Umbilical cord‐derived mesenchymal stem cells; UCMSNs: NaGdF4:Yb,Er@NaGdF4:Yb@NaNdF4@mSiO2-CuS-PEG; US: Ultrasound; Yb3+: ytterbium trivalent ion